查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844436

肥胖治療市場按治療類型、藥物類別、給藥途徑、患者年齡層、分銷管道和最終用戶分類－2025-2032 年全球預測

Obesity Treatment Market by Treatment Type, Drug Class, Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年肥胖治療市場規模將成長至 294.6 億美元，複合年成長率為 8.39%。

主要市場統計數據
基準年2024年 154.6億美元
預計2025年 166.9億美元
預測年份：2032年 294.6億美元
複合年成長率（%） 8.39%

明確的臨床創新方向、系統層級挑戰和策略重點將重塑肥胖照護服務和相關人員的商業機會

肥胖治療處於臨床創新、患者期望變化和醫療保健政策演變的交匯點，需要細緻的策略性思維。藥物治療的進展，尤其是基於腸促胰島素的治療方法，正在透過提供新的​​非手術治療方案來重塑治療模式，這些方案正在改變護理途徑、患者轉診模式和付款人關係。同時，外科手術也在不斷發展，擁有更微創的技術和更完善的手術全期護理，在臨床嚴重程度和合併症情況需要持久的解剖干預時，外科手術仍能發揮作用。

醫療保健提供者、藥品開發商、醫療設備製造商和付款人必須協調這些臨床進展與持續存在的挑戰，包括不同人群之間獲取藥物的不一致、報銷框架碎片化，以及原料藥和給藥設備供應鏈面臨的壓力。數位醫療、遠端監控和患者參與平台的創新正開始填補後續護理和行為介入的空白，但要取得可衡量的成果，必須將其融入現有的護理生態系統。因此，將臨床證據產生與切實可行的獲取策略和跨學科夥伴關係關係相結合的利益相關人員，將最有能力影響患者治療結果和組織績效。

本引言重點闡述了相互關聯的變革促進因素——臨床有效性、交付方式、監管途徑和商業策略——並為尋求實用、循證指導的決策者設定了期望，從而為後續分析奠定了基礎。接下來的敘述將分析該領域的變革力量、監管和貿易阻力、細分市場對產品和服務設計的影響，以及在建立長期韌性的同時應對短期衝擊的可行建議。

不斷發展的臨床範式、交付方式和付款人期望正在推動肥胖治療從偶發性干預向縱向綜合護理模式的系統轉變。

肥胖治療領域正在經歷一場變革性的轉變，這得益於藥物治療的突破、外科手術的改進以及數位化療法的日趨成熟。針對代謝和食慾調節路徑的藥物治療已證實具有臨床意義的減重效果，並具有更廣泛的心臟代謝益處。這一轉變正在加速整合內分泌、基層醫療、行為健康和營養服務的多學科護理模式，從而增加持續患者管理的接觸點。

同時，減重手術和微創手術的創新改善了手術全期的安全性和恢復時間，為晚期疾病或難治性藥物治療患者提供了手術選擇。給藥方式也日趨多樣化，口服和腸外給藥並存，每種途徑對依從性、儲存和病人支持有不同的需求。隨著臨床技術的進步，分銷管道也不斷發展。零售店和專科診所模式正在適應全通路患者病人歷程，其中面對面諮詢、遠端醫療追蹤和電子商務履約必須協調一致，以確保護理的連續性。

政策和支付方環境的調整並不均衡，一些支付方正在擴大藥物治療的覆蓋範圍，而另一些支付方則要求療效可證實。這種可及性方面的差異加劇了差異，並獎勵製造商開發強力的現實世界證據和基於價值的合約模式。總體而言，該領域正在從偶發性介入轉向縱向管理框架，強調持續療效、患者體驗和經濟價值，並將臨床創新與系統思維相結合。

預計 2025 年的貿易政策調整將對營運、定價和准入產生複合影響，因此需要採取積極主動的參與策略來增強供應鏈的彈性和補償

2025年美國加徵關稅或貿易政策變化將產生一系列累積影響，肥胖照護生態系統的相關人員必須評估並減輕這些影響。對進口活性藥物成分、給藥裝置或特殊醫療設備徵收關稅將增加依賴全球供應鏈的製造商的投入成本。這些成本壓力可能會透過分銷管道層層疊加，影響標價、返利策略以及與付款人和醫療保健提供者的談判動態。價格變動的幅度將取決於合約結構和治療類別內的競爭強度。

除了直接的成本影響外，關稅還可能改變供應商的行為和投資計畫。供應商可能會補充生產庫存、實現採購多元化或投資更高的庫存緩衝，以降低貿易政策波動帶來的風險。此類策略舉措需要資金和時間，並可能隨著產能的重新分配在短期至中期內導致供應曲折點。對於腸外治療和一次性給藥裝置，無菌和監管核准限制了供應商的兼容性，因此任何中斷都可能對供給能力和臨床運作產生重大影響。減重護理機構可能面臨設備和植入成本的增加，這會影響治療經濟性和個案選擇標準。

關稅導致的成本上升也將影響研發的優先順序。企業可能需要重新評估其在研專案投資，或優先考慮那些對低風險進口產品依賴程度較低的計劃。在支付者和提供者層面，成本上升可能會加強對比較有效性和長期療效的審查，從而加速對真實世界證據和衛生經濟分析的需求。從公共衛生角度來看，減少可負擔醫療服務和醫療可近性的政策可能會加劇現有的差距，並對醫療保健機會有限或肥胖基準盛行率較高的人群造成不成比例的影響。因此，全面的緩解策略（例如，實現採購來源多元化、與相關人員簽訂合作合約、盡可能投資國內製造以及積極主動地與相關人員溝通）對於保持醫療服務的連續性和維持治療應用的勢頭至關重要。

將治療方式、藥理類別、給藥途徑、患者群體、管道和護理環境與策略挑戰聯繫起來的觀點

細分分析揭示了治療方式、藥理機制、給藥途徑、患者人口統計、分銷管道和最終用戶環境之間複雜的相互作用，每種相互作用都對臨床實踐和商業策略有著獨特的影響。根據治療類型，可分為藥物治療和外科手術，其中藥物治療又分為非處方藥和處方藥；外科手術則包括減肥手術、胃繞道手術和腹腔鏡手術。這些差異至關重要，因為每種治療途徑都涉及不同的臨床決策點、監管要求和患者教育需求，這決定了從初次諮詢到長期隨訪，患者就診病人歷程中相關人員的類型。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • GLP-1受體促效劑廣泛整合到基層醫療肥胖症通訊協定中
  • 提供個人化肥胖管理方案的數位治療平台的出現
  • 擴大使用針對多種代謝途徑的聯合藥物療法來治療肥胖症
  • 擴展虛擬減重指導，整合人工智慧驅動的行為改變支持
  • 增加對用於慢性體重管理介入的植入式神經刺激設備的投資
  • 開發個人化基因篩檢來指導針對性肥胖治療的選擇和劑量
  • 生物製藥公司與科技Start-Ups建立新夥伴關係，加速肥胖治療創新進程
  • 擴大付款人報銷模式，涵蓋遠端醫療肥胖服務和遠端監控解決方案

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章肥胖治療市場（依治療類型）

  • 藥物治療
    • 非處方藥
    • 處方藥
  • 外科手術
    • 減重手術
    • 胃繞道手術
    • 腹腔鏡手術

第9章肥胖治療市場（依藥物類別）

  • 食慾抑制劑
  • GLP-1受體促效劑
  • 脂肪酶抑制劑
  • 代謝加速器

第 10 章肥胖治療市場（依給藥途徑）

  • 口服
  • 腸外

第 11 章肥胖治療市場（依患者年齡層）

  • 成人
  • 老年人
  • 孩子們

第 12 章肥胖治療市場（依通路）

  • 線下零售
  • 網路零售

第 13 章肥胖治療市場（按最終用戶分類）

  • 醫院和診所
  • 專科診所
  • 減重與健康中心

第 14 章肥胖治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章肥胖治療市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章肥胖治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Apollo Endosurgery, Inc.
    • AstraZeneca PLC
    • Atkins Nutritionals, Inc.
    • BTL Aesthetics
    • CH Boehringer Sohn AG & Ko. KG
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc.
    • Herbalife Ltd.
    • Johnson & Johnson Services, Inc.
    • Kellogg Company
    • Medtronic PLC
    • Merck & Co.
    • Novo Nordisk A/S
    • NutriSystem, Inc.
    • Olympus Corporation
    • Pfizer, Inc.
    • ReShape Lifesciences, Inc.
    • Rhythm Pharmaceuticals, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Viking Therapeutics, Inc.
    • VIVUS LLC
    • Zealand Pharma A/S
Product Code: MRR-EC2E133E32E2

The Obesity Treatment Market is projected to grow by USD 29.46 billion at a CAGR of 8.39% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.46 billion
Estimated Year [2025] USD 16.69 billion
Forecast Year [2032] USD 29.46 billion
CAGR (%) 8.39%

A clear orientation to the converging clinical innovations, system-level challenges, and strategic priorities that are reshaping obesity treatment delivery and stakeholder opportunity

Obesity treatment sits at the intersection of clinical innovation, shifting patient expectations, and evolving health policy, creating a landscape that demands nuanced strategic thinking. Advances in pharmacotherapy-most notably in incretin-based therapies-have reframed treatment paradigms by offering new non-surgical options that alter care pathways, patient referral patterns, and payer interactions. At the same time, surgical interventions continue to evolve with less invasive techniques and refined perioperative care, maintaining their role where clinical severity and comorbidity profiles necessitate durable anatomical interventions.

Healthcare providers, pharmaceutical developers, device manufacturers, and payers must reconcile these clinical advances with persistent challenges: inconsistent access across demographic groups, fragmented reimbursement frameworks, and pressures on supply chains for active pharmaceutical ingredients and delivery devices. Innovations in digital health, remote monitoring, and patient engagement platforms are beginning to close gaps in follow-up care and behavioral intervention, yet they require integration into existing care ecosystems to deliver measurable outcomes. Consequently, stakeholders who align clinical evidence generation with pragmatic access strategies and cross-disciplinary partnerships will be best positioned to influence both patient outcomes and organizational performance.

This introduction frames the subsequent analysis by emphasizing the interconnected drivers of change-clinical efficacy, delivery modality, regulatory pathways, and commercial strategy-and sets expectations for decision-makers seeking pragmatic, evidence-based guidance. The narrative that follows dissects transformative forces in the field, regulatory and trade headwinds, segmentation-level implications for product and service design, and actionable recommendations to navigate near-term disruption while building long-term resilience.

Evolving clinical paradigms, delivery modalities, and payer expectations are driving a systemic shift from episodic intervention toward longitudinal integrated care models for obesity treatment

The obesity treatment landscape is undergoing transformative shifts driven by breakthroughs in pharmacotherapy, refinements in surgical practice, and the maturation of digital therapeutics. In pharmacology, therapies that harness metabolic and appetite-regulating pathways have demonstrated clinically relevant weight reductions tied to broader cardiometabolic benefits, prompting clinicians and payers to reevaluate lines of therapy and treatment sequencing. This shift is accelerating multidisciplinary care models that integrate endocrinology, primary care, behavioral health, and nutrition services, creating more touchpoints for sustained patient management.

At the same time, procedural innovation in bariatric and minimally invasive surgery has improved perioperative safety and recovery timelines, preserving the role of surgical options for patients with advanced disease or refractory responses to medical therapy. Delivery modalities are also diversifying: oral formulations and parenteral administration coexist, and each route creates distinct adherence, storage, and patient support needs. Parallel to clinical advances, distribution channels are evolving. Retail and specialty clinic models are adapting to omnichannel patient journeys where in-person consultations, telemedicine follow-ups, and e-commerce fulfillment must be coordinated to ensure continuity of care.

Policy and payer landscapes are adapting unevenly, with some payers expanding coverage for pharmacologic therapies contingent on demonstrable outcomes, while others maintain restrictive criteria. This differential access amplifies disparities and incentivizes manufacturers to develop robust real-world evidence and value-based contracting approaches. Overall, the sector is shifting from episodic interventions toward longitudinal management frameworks that blend clinical innovation with systems thinking, emphasizing sustained outcomes, patient experience, and economic value.

Projected trade policy adjustments in 2025 will create compounding operational, pricing, and access implications that necessitate proactive supply chain resilience and reimbursement engagement strategies

The introduction of additional tariffs or trade policy changes in the United States in 2025 introduces a set of cumulative effects that stakeholders across the obesity treatment ecosystem must evaluate and mitigate. Tariffs on imported active pharmaceutical ingredients, delivery devices, or specialized medical equipment would increase input costs for manufacturers that rely on global supply chains. Those cost pressures are likely to cascade through distribution channels, influencing list prices, rebate strategies, and negotiation dynamics with payers and healthcare providers. The magnitude of price transmission will vary depending on contracting structures and the competitive intensity within therapeutic categories.

Beyond immediate cost impacts, tariffs can alter supplier behavior and investment timelines. Suppliers may reshore production, diversify sourcing, or invest in higher inventory buffers to reduce exposure to trade policy volatility. Such strategic moves require capital and time and may lead to short- to medium-term supply inflection points as capacity is reallocated. For parenteral therapies and single-use delivery devices, where sterility and regulatory approvals constrain supplier interchangeability, any disruption can have outsized effects on availability and clinical operations. Facilities that perform bariatric procedures may face increased equipment and implant costs that influence procedural economics and case selection criteria.

Tariff-driven cost increases also have implications for research and development prioritization. Companies may need to reassess pipeline investments or prioritize projects with lower dependency on at-risk imports. At the payer and provider level, increased costs could intensify scrutiny around comparative effectiveness and long-term outcomes, accelerating demand for real-world evidence and health economic analyses. In public health terms, policies that reduce affordability or access could exacerbate existing disparities, disproportionately affecting populations with limited healthcare access or higher baseline prevalence of obesity. Consequently, comprehensive mitigation strategies-including sourcing diversification, collaborative contracting with payers, investment in domestic manufacturing where feasible, and proactive stakeholder communication-are essential to preserve continuity of care and maintain momentum in therapeutic adoption.

A multi-dimensional segmentation perspective connecting treatment modalities, pharmacologic classes, administration routes, patient cohorts, channels, and care settings to strategic imperatives

Segmentation analysis reveals the complex interplay among treatment modalities, pharmacologic mechanisms, administration routes, patient demographics, distribution channels, and end-user settings, each of which carries distinct implications for clinical practice and commercial strategy. Based on treatment type, the landscape includes pharmacotherapy and surgical procedures; pharmacotherapy further divides into over-the-counter drugs and prescription medications, while surgical procedures encompass bariatric surgery, gastric bypass, and laparoscopic surgery. These distinctions matter because each pathway involves different clinical decision points, regulatory requirements, and patient education needs, and they determine the types of stakeholders involved in patient journeys from initial consultation through long-term follow-up.

Based on drug class, therapeutic approaches span appetite suppressants, GLP-1 receptor agonists, lipase inhibitors, and metabolism boosters, each presenting unique efficacy, safety, and monitoring profiles that inform both prescriber behavior and payer criteria. Based on route of administration, the market includes oral and parenteral options; oral therapies offer convenience and potentially broader uptake, while parenteral agents may deliver higher efficacy or different tolerability characteristics and will require administration support and cold-chain logistics. Based on patient age group, stakeholders must address the different clinical needs and adherence challenges of adults, elderly patients, and pediatric populations, paying particular attention to dosing, comorbidity profiles, and long-term follow-up strategies.

Based on distribution channel, treatment access occurs through offline retail and online retail models; offline settings continue to play a critical role for procedural interventions and in-person clinical management, while online channels expand access for certain pharmacologic therapies and ongoing patient support. Based on end-user, services and products are delivered across hospitals and clinics, specialty clinics, and weight loss and wellness centers, each with distinct procurement practices, clinical workflows, and reimbursement environments. Integrating these segmentation lenses reveals where product design, channel strategy, and evidence generation must align to meet clinical needs and payer expectations across diverse patient cohorts and care settings.

Distinct regional regulatory, reimbursement, and cultural dynamics across the Americas, Europe Middle East Africa, and Asia Pacific require tailored access and evidence strategies

Regional dynamics vary significantly and require differentiated approaches to regulatory engagement, access strategy, and partnership development. In the Americas, regulatory pathways in North America leverage robust clinical trial infrastructure and more mature payer frameworks, producing rapid adoption cycles for high-efficacy therapies where reimbursement aligns with demonstrated outcomes. Health systems in the region are also contending with substantial unmet need and demographic heterogeneity, which creates opportunities for integrated care models and value-based contracting that tie reimbursement to sustained clinical benefit.

In Europe, the Middle East & Africa, regulatory regimes present a patchwork of approval timelines and reimbursement criteria that necessitate targeted market entry planning and local evidence generation. Several countries prioritize cost-effectiveness and comparative analyses within health technology assessment frameworks, driving the need for region-specific real-world data and economic models. In many emerging markets across these regions, infrastructure constraints and out-of-pocket payment prevalence affect the feasible adoption pathways for both pharmacologic and surgical interventions.

In the Asia-Pacific region, market heterogeneity includes advanced markets with sophisticated regulatory systems alongside rapidly developing health systems where rising prevalence and growing middle-class demand are increasing access to obesity treatments. Supply chain considerations, local manufacturing capacities, and regional regulatory harmonization efforts influence launch sequencing and commercial investments. Across all regions, cultural perceptions of obesity, provider training, and the availability of multidisciplinary care teams shape adoption curves and long-term treatment paradigms, making localized stakeholder engagement and tailored evidence packages essential for successful program implementation.

Competitive advantage will accrue to organizations that combine differentiated clinical outcomes evidence, integrated care partnerships, and adaptable commercial and supply chain capabilities

Competitive dynamics are increasingly defined by the ability to demonstrate differentiated clinical outcomes, optimize delivery and support services, and engage payers with persuasive health economic evidence. Leading biopharmaceutical developers are investing in outcome studies and patient support programs to address adherence, persistence, and long-term safety monitoring, while device and procedural innovators emphasize improved perioperative pathways and enhanced recovery protocols to reduce complications and total episode costs. Partnerships between drug developers and specialty clinics or digital health providers are emerging as a way to integrate behavioral interventions, remote monitoring, and adherence support into commercial offerings, increasing the perceived value for payers and patients alike.

Strategic capabilities that separate successful organizations from peers include robust real-world evidence generation, flexible manufacturing and supply chain arrangements, and sophisticated payer engagement models that can support value-based reimbursement. Companies that invest in education for clinicians and allied health professionals, while simultaneously scaling patient engagement tools, stand to accelerate adoption and improve outcomes. Additionally, cross-sector collaboration-spanning pharmaceuticals, device manufacturers, health systems, and technology providers-creates opportunities to deliver end-to-end solutions that address both the biological and behavioral components of obesity, positioning organizations to capture more of the continuum of care.

Practical and coordinated actions for leaders to fortify supply chains, build value-based evidence, and expand integrated patient delivery models to safeguard access and accelerate adoption

Industry leaders should pursue a coordinated set of actions that align clinical evidence generation, supply chain resilience, and payer engagement to preserve access and sustain innovation. First, diversify sourcing and invest in regional manufacturing or strategic supplier partnerships to mitigate exposure to trade policy disruptions and to reduce lead-time risk for critical inputs such as active pharmaceutical ingredients and single-use devices. Complement supply-side measures with inventory optimization and contractual clauses that allow for flexibility during periods of geopolitical uncertainty.

Second, prioritize the generation of rigorous real-world evidence and health economic models that demonstrate long-term value across relevant patient populations and care settings. Use pragmatic trials, registries, and payer data partnerships to quantify outcomes that matter to payers, including reductions in comorbidity burden, hospital utilization, and total cost of care. Third, innovate in patient support and delivery models: integrate digital therapeutics, remote monitoring, and multidisciplinary care coordination to improve adherence and persistence, while reducing the burden on brick-and-mortar facilities.

Fourth, engage proactively with payers and health technology assessment bodies to design reimbursement pathways that reflect longitudinal benefits rather than short-term cost metrics. Consider pilots for outcomes-based contracts that align pricing to sustained clinical endpoints. Fifth, tailor regional market entry and commercialization strategies to local regulatory requirements, cultural contexts, and infrastructure realities, using local partnerships to expedite uptake. Finally, invest in workforce development by equipping clinicians, nurses, and allied health professionals with the training and tools needed to deliver complex chronic-disease management effectively. Together, these actions will strengthen organizational resilience and help sustain patient access during periods of disruption.

A layered research methodology blending primary stakeholder interviews, targeted secondary intelligence, and rigorous triangulation to ensure actionable and defensible insights

The research approach combines a layered methodology designed to triangulate insights from diverse and credible sources. The primary research component includes structured interviews with clinicians, payers, procurement leaders, and patient advocacy representatives to capture firsthand perspectives on clinical decision-making, reimbursement constraints, and access barriers. Supplementing these interviews, expert advisory panels provide thematic validation and scenario testing to stress-test strategic assumptions and to surface emerging operational risks.

Secondary research draws on peer-reviewed clinical literature, regulatory filings, public policy documents, and published guidance from relevant health authorities to construct the clinical and regulatory context. Commercial intelligence is gathered from company disclosures, trial registries, and patent landscapes to map competitive positioning and innovation trajectories. Where appropriate, real-world datasets and claims analyses are used to assess utilization patterns and care pathways, while methodological safeguards-such as data cleaning, outlier analysis, and triangulation-ensure analytical rigor.

Analytical techniques include thematic synthesis for qualitative inputs, comparative regulatory analysis, and health economic modeling frameworks to interpret cost and outcome relationships qualitatively. Limitations of the methodology are acknowledged: stakeholder perspectives may evolve rapidly with new clinical data or policy changes, and access to certain proprietary datasets can constrain granularity. To mitigate these limitations, iterative updates and targeted follow-up interviews are recommended following major regulatory or clinical developments.

A concise synthesis emphasizing the strategic imperative to combine clinical evidence, operational resilience, and payer engagement to enhance outcomes and sustain access

The obesity treatment ecosystem is at an inflection point where clinical innovation, supply chain realities, and payer expectations converge to redefine care pathways. Stakeholders that proactively align evidence generation with pragmatic access strategies and resilient operational planning will capture disproportionate value while improving patient outcomes. The interplay between pharmacologic advances and procedural care underscores the need for integrated, multidisciplinary approaches that account for patient heterogeneity and long-term management needs.

Managing near-term risks-such as trade policy shifts, supply chain constraints, and reimbursement variability-requires deliberate actions that include sourcing diversification, targeted real-world evidence development, and close payer collaboration. Simultaneously, investments in digital care models and patient support mechanisms can enhance adherence and extend the benefits of clinical advances to broader patient populations. In sum, the path forward favors organizations that balance scientific rigor with operational agility and who partner across the care continuum to deliver measurable, sustainable improvements in patient health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Widespread integration of GLP-1 receptor agonists into primary care obesity protocols
  • 5.2. Emergence of digital therapeutics platforms offering personalized obesity management programs
  • 5.3. Increasing use of combination pharmacotherapy targeting multiple metabolic pathways for obesity
  • 5.4. Expansion of virtual weight loss coaching integrating AI driven behavioral change support
  • 5.5. Rising investment in implantable neurostimulation devices for chronic weight management interventions
  • 5.6. Growth of personalized genetic screening to guide targeted obesity therapy selection and dosing
  • 5.7. Emerging partnerships between biopharma and tech startups to accelerate obesity treatment innovation pipelines
  • 5.8. Expansion of insurer reimbursement models covering telehealth obesity services and remote monitoring solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obesity Treatment Market, by Treatment Type

  • 8.1. Pharmacotherapy
    • 8.1.1. Over-The-Counter Drugs
    • 8.1.2. Prescription Medications
  • 8.2. Surgical Procedures
    • 8.2.1. Bariatric Surgery
    • 8.2.2. Gastric Bypass
    • 8.2.3. Laparoscopic Surgery

9. Obesity Treatment Market, by Drug Class

  • 9.1. Appetite Suppressants
  • 9.2. GLP-1 Receptor Agonists
  • 9.3. Lipase Inhibitors
  • 9.4. Metabolism Boosters

10. Obesity Treatment Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Obesity Treatment Market, by Patient Age Group

  • 11.1. Adults
  • 11.2. Elderly
  • 11.3. Pediatric

12. Obesity Treatment Market, by Distribution Channel

  • 12.1. Offline Retail
  • 12.2. Online Retail

13. Obesity Treatment Market, by End-User

  • 13.1. Hospitals & Clinics
  • 13.2. Specialty Clinics
  • 13.3. Weight Loss & Wellness Centers

14. Obesity Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Obesity Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obesity Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Apollo Endosurgery, Inc.
    • 17.3.3. AstraZeneca PLC
    • 17.3.4. Atkins Nutritionals, Inc.
    • 17.3.5. BTL Aesthetics
    • 17.3.6. C.H. Boehringer Sohn AG & Ko. KG
    • 17.3.7. Eli Lilly and Company
    • 17.3.8. F. Hoffmann-La Roche Ltd
    • 17.3.9. GlaxoSmithKline plc.
    • 17.3.10. Herbalife Ltd.
    • 17.3.11. Johnson & Johnson Services, Inc.
    • 17.3.12. Kellogg Company
    • 17.3.13. Medtronic PLC
    • 17.3.14. Merck & Co.
    • 17.3.15. Novo Nordisk A/S
    • 17.3.16. NutriSystem, Inc.
    • 17.3.17. Olympus Corporation
    • 17.3.18. Pfizer, Inc.
    • 17.3.19. ReShape Lifesciences, Inc.
    • 17.3.20. Rhythm Pharmaceuticals, Inc.
    • 17.3.21. Sanofi SA
    • 17.3.22. Takeda Pharmaceutical Company Limited
    • 17.3.23. Viking Therapeutics, Inc.
    • 17.3.24. VIVUS LLC
    • 17.3.25. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OBESITY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 313. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 318. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 319. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 320. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 321. GCC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 330. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)

TABL